Introduction ECMO (extra-corporeal membrane oxygenation) is a form of extracorporeal life support. An external artificial circulation or circuit carries venous blood from the patient to an oxygenator, where oxygen is added and carbon dioxide removed, then the blood is returned to the patient circulation. Flow through the circuit may be achieved either using a pump (centrifugal or roller) or pumpless circuit using the patient's own arterio-venous pressure gradient.
In 1975, Zapol and colleagues reported a prospective randomised trial of veno-arterial ECMO in adults with acute respiratory distress syndrome (ARDS). This nine centre study showed survival rates of 10% in both the control and ECMO treated group. 1 The high mortality rates and other problems associated with earlier techniques led to a decline in its use over the following decades.
Improvements in technology have meant significant advances in pumps, circuits and oxygenators, resulting in more efficient gas exchange with less resistance to flow, decreased haemolysis and plasma leak that were problems associated with earlier circuits.
A randomised control trial of its use in ARDS (CESAR) is anticipated. Encouraging results from a number of other groups worldwide, especially when used to treat children, have led to an increase in its use in many centres. A number of centres report survival rates of 50-70% in patients with ARDS treated with ECMO.
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Types of ECMO ECMO can be either veno-venous (VV) or veno-arterial (VA).
With VV ECMO, blood is taken from a large central vein and returned to the venous system near the right atrium after it has passed through an external circuit and oxygenator. A variant of this (high flow VV ECMO) uses two access cannulae to remove venous blood from the patient before entering the oxygenator. High flow VV ECMO is used when circuit flow via a single access cannula is inadequate to maintain safe oxygenation and is used for more severe cases of respiratory failure or high cardiac output states. VV ECMO is used to treat isolated respiratory failure when adequate heart function is present.
Peripheral VA ECMO involves peripheral cannulation, eg femoral vein -femoral artery, allowing venous blood to be taken from large central veins and returned to the patient's arterial system after it has passed through an oxygenator. VA ECMO is used for the treatment of patients with cardio-respiratory or cardiac failure when the use of a ventricular assist device (VAD) is deemed inappropriate, or as a bridge to transplant or VAD insertion.
Central VA ECMO, in which the cannulae are attached directly to the major vessels (including the ascending aorta) during surgery, is required for cardiac support when there is poor lung function, because the use of peripheral VA ECMO in this case would lead to the delivery of hypoxic blood from the pulmonary circulation preferentially to the cerebral and coronary circulation. Peripheral VA ECMO is appropriate when there is reasonable lung function and cardiac surgery is not required.
Indications
ECMO is indicated for potentially reversible, life-threatening forms of respiratory and/or cardiac failure which are unresponsive to conventional therapy. Common uses of VA ECMO include: graft failure post heart/heart-lung transplant, cardiogenic shock, post cardiac surgery when weaning from cardiopulmonary bypass using conventional methods fails, sepsis with profound cardiac depression, and drug overdose with profound cardiac depression. There are a number of other, less common, indications such as myocarditis, chronic cardiomyopathy as a bridge to transplant / VAD insertion, pulmonary embolism, cardiac or major vessel trauma, massive haemoptysis, pulmonary trauma and acute anaphylaxis.
VV ECMO can be used in patients who are hypoxaemic because of severe pneumonia, ARDS, acute lung (graft) failure following transplant, pulmonary contusion, airway obstruction, status asthmaticus, pulmonary aspiration syndromes, alveolar proteinosis and smoke inhalation.
Case Series
Between March 2004 and April 2006, we treated 10 patients with VV or VA ECMO in St Vincent's Intensive Care Unit, Sydney, Australia. Of these, 5 had VV ECMO and 5, VA ECMO. Of this cohort, 7 patients survived to discharge from hospital (70% survival rate). The indication, type of ECMO and mortality for this cohort are shown in table 1.
Discussion
The survival rate in this series is in the order of that seen in other studies. [2] [3] [4] [5] [6] [7] ECMO is a form of extracorporeal life support which should be reserved for patients with reversible cardiac or respiratory failure which is not responding to maximal medical therapy, at the discretion of the treating physician.
Treatment with ECMO is not without associated risks, including bleeding, limb ischaemia, difficulty with fluid shifts and volume replacement, problems associated with anticoagulation, weaning and reinstituting mechanical ventilation, and other problems associated with multiple organ support. Original Articles 12 and an anticoagulation protocol is used. After successful guidewire insertion for ECMO cannulae, a 5,000-10,000U bolus of heparin is given to maintain an ACT of >200 seconds. The ACT level is used to titrate the heparin dose in the first 24 hours, and measured six hourly. Target ACT in the non-bleeding patient with a platelet count >80,000/ mm 3 is 140-180 seconds. After 24 hours, the APTT is used for monitoring, with a target range of 60-70 seconds. Plasma free haemoglobin is also measured, aiming for a safe level of <0.1 g/l. Protamine administration is contraindicated as it can cause circuit related thrombosis.
Bleeding is a life threatening complication of ECMO treatment.
There is a balance between systemic anticoagulation and the risks of bleeding, and the risk of thrombosis. Careful monitoring, prompt treatment of bleeding and assessment of signs of thrombosis are essential.
HIT is also well described in the literature. Cessation of heparin and use of other anticoagulants such as bivalirudin (direct thrombin inhibitor), 8 and lepirudin 9, 10 have been described to deal with this problem.
Ventilator Settings VV ECMO is used to treat isolated respiratory failure when there is adequate heart function. Once commenced on ECMO, intermittent positive pressure ventilation can be reduced. It is current practice to wean mechanical ventilatory support to approximately 4 breaths per minute; PEEP is usually kept high, and pressure support reduced to prevent alveolar collapse and reduce volu/ barotrauma. This rests the lungs until the pulmonary disease process is reversed.
PaCO 2 levels can be controlled by altering the flow rate of oxygen into the circuit.
Weaning
Weaning of ECMO should be undertaken when there is evidence of reversal of the pathological process leading to cardio-respiratory failure. It is a gradual process, and involves increasing mechanical ventilatory support whilst reducing support given by the ECMO circuit. Careful monitoring of vital signs and arterial blood gas analysis and the patient's overall condition must all be taken into account.
To wean VA ECMO, the circuit flows must be reduced so that native cardiac function can be assessed (transoesophageal echocardiography (TOE) is useful for this). Ventilatory support must be increased and oxygenator gas flow settings adjusted. Additional heparin may be required to prevent thrombosis at this time, because as ECMO flow rates are reduced there is an increased risk of thrombosis due to stasis. When flow rates are less than 1.5 l/m it is possible to assess the oxygenation achieved exclusively by ventilation by turning off the gas flow to the oxygenator. This creates an artificial right to left shunt, which if tolerated suggests that native respiratory function is adequate to achieve gas exchange off ECMO.
Weaning of VV ECMO is best achieved by turning off the gas flow to the oxygenator and increasing mechanical ventilation. Circuit flow should not be reduced until adequate function is assessed without ECMO support (TOE is not required, nor an increase in anticoagulation).
Other Problems
The risk of lower limb ischaemia associated with VA ECMO can be reduced by the insertion of a distal bypass to supply the distal limb of the leg with the arterial cannula. This involves inserting a side arm into the arterial line which can be placed to supply the distal limb with oxygenated blood.
Problems with hypovolaemia and 'sucking down' of the access cannula can be overcome by using two cannulae to supply the venous limb of the ECMO circuit. This also reduces the need for fluid volume loading and the associated risk of interstitial oedema.
Conclusion
Through lessons which have been learned from this series, and through national and international sharing of experience, associated morbidity should decrease.
The main determinant of mortality is, perhaps, the choice of appropriate patients. With experience, it is easier to identify patients and disease processes which respond to ECMO. ECMO is currently a rescue therapy that is available to the physician when maximal medical therapy fails. With the relevant expertise and resources, it is a treatment which could be used more frequently in intensive care units in the UK.
